Artificial tear preparations are important in the management of
dry eye syndrome. We present the findings from four recently published studies conducted in Russia assessing Hylabak(®) (marketed as Hyabak(®) in Europe), a preservative-free
hyaluronic acid preparation, for the treatment of
dry eye syndrome. All studies had an open, noncomparative design, but one compared the findings with those from 25 patients treated with Tear Naturale(®) in previous studies. A total of 134 children and adults were enrolled, and the etiologies of
dry eye syndrome included
contact lens use, intensive office work, adenovirus
eye infection, postmenopausal status, persistent meibomian
blepharitis, Sjögren's syndrome,
phacoemulsification with
intraocular lens implantation, and
refractive surgery. The patients were treated with Hylabak for 2 weeks to 2 months. All studies showed that Hylabak resulted in marked improvement as assessed by subjective sensations/complaints, Schirmer's test, Norn's test, impression cytology and biomicroscopy, staining, and tear osmolarity. Greater benefits were also reported compared with Tear Naturale, including a faster onset of action. Hylabak was well tolerated. In conclusion, Hylabak provided rapid and safe relief from the signs and symptoms of
dry eye syndrome, as well as improvement in objective measures, in a wide range of patients.